JP6915865B2 - NO production inhibitor and metastasis / infiltration inhibitor for solid tumors - Google Patents
NO production inhibitor and metastasis / infiltration inhibitor for solid tumors Download PDFInfo
- Publication number
- JP6915865B2 JP6915865B2 JP2017193428A JP2017193428A JP6915865B2 JP 6915865 B2 JP6915865 B2 JP 6915865B2 JP 2017193428 A JP2017193428 A JP 2017193428A JP 2017193428 A JP2017193428 A JP 2017193428A JP 6915865 B2 JP6915865 B2 JP 6915865B2
- Authority
- JP
- Japan
- Prior art keywords
- inhibitor
- tumor
- ikd
- infiltration
- metastasis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
本発明は、ＮＯ産生抑制剤及び固形腫瘍に対する転移・浸潤抑制剤に関する。 The present invention relates to a NO production inhibitor and a metastasis / infiltration inhibitor for solid tumors.
ＩＫＤ-８３４４は、放線菌から単離された２８員環のマクロライド系の抗生物質であるが、殺虫剤など（例えば、特許文献１参照）や、医薬としての抗菌剤や白血病細胞に対する増殖抑制剤（例えば、特許文献２参照）としても知られている。現在まで、化学合成の方法も報告されている（例えば、特許文献２、非特許文献１〜３参照）。
IKD-8344 is a 28-membered ring macrolide antibiotic isolated from actinomycetes. It is also known as an agent (see, for example, Patent Document 2). To date, methods of chemical synthesis have also been reported (see, for example, Patent Document 2 and
本発明は、新規ＮＯ産生抑制剤及び固形腫瘍に対する新規転移・浸潤抑制剤を提供することを目的とする。 An object of the present invention is to provide a novel NO production inhibitor and a novel metastasis / infiltration inhibitor for solid tumors.
本発明の一実施態様は、下記構造式（Ｉ）を有する化合物またはその薬学的に許容できる塩を有効成分として含有する、ＮＯ産生抑制剤である。 One embodiment of the present invention is a NO production inhibitor containing a compound having the following structural formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient.
本発明の他の一実施態様は、固形腫瘍に対する腫瘍転移抑制剤であって、下記構造式（Ｉ）を有する化合物またはその薬学的に許容できる塩を有効成分として含有する腫瘍転移抑制剤である。 Another embodiment of the present invention is a tumor metastasis inhibitor for a solid tumor, which is a tumor metastasis inhibitor containing a compound having the following structural formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient. ..
また、この腫瘍転移抑制剤は、前記固形腫瘍に対する腫瘍細胞増殖抑制効果を有する抗腫瘍剤と併用されてもよい。 In addition, this tumor metastasis inhibitor may be used in combination with an antitumor agent having a tumor cell proliferation inhibitory effect on the solid tumor.
本発明のさらなる一実施態様は、固形腫瘍に対する腫瘍浸潤抑制剤であって、下記構造式（Ｉ）を有する化合物またはその薬学的に許容できる塩を有効成分として含有する腫瘍浸潤抑制剤である。 A further embodiment of the present invention is a tumor infiltration inhibitor for a solid tumor, which contains a compound having the following structural formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient.
また、この腫瘍浸潤抑制剤は、前記固形腫瘍に対する腫瘍細胞増殖抑制効果を有する抗腫瘍剤と併用されてもよい。 In addition, this tumor infiltration inhibitor may be used in combination with an antitumor agent having a tumor cell proliferation inhibitory effect on the solid tumor.
本発明によって、新規ＮＯ産生抑制剤及び固形腫瘍に対する新規転移・浸潤抑制剤を提供することができるようになった。 INDUSTRIAL APPLICABILITY According to the present invention, it has become possible to provide a novel NO production inhibitor and a novel metastasis / infiltration inhibitor for solid tumors.
実施の形態及び実施例に特に説明がない場合には、M. R. Green & J. Sambrook (Ed.), Molecular cloning, a laboratory manual (4th edition), Cold Spring Harbor Press, Cold Spring Harbor, New York (2012); F. M. Ausubel, R. Brent, R. E. Kingston, D. D. Moore, J.G. Seidman, J. A. Smith, K. Struhl (Ed.), Current Protocols in Molecular Biology, John Wiley & Sons Ltd.などの標準的なプロトコール集に記載の方法、あるいはそれを修飾したり、改変した方法を用いる。また、市販の試薬キットや測定装置を用いる場合には、特に説明が無い場合、それらに添付のプロトコールを用いる。 Unless otherwise specified in embodiments and examples, MR Green & J. Sambrook (Ed.), Molecular cloning, a laboratory manual (4th edition), Cold Spring Harbor Press, Cold Spring Harbor, New York (2012) ); FM Ausubel, R. Brent, RE Kingston, DD Moore, JG Seidman, JA Smith, K. Struhl (Ed.), Current Protocols in Molecular Biology, John Wiley & Sons Ltd. Or the method of modifying or modifying it. When using a commercially available reagent kit or measuring device, the protocol attached to them is used unless otherwise specified.
なお、本発明の目的、特徴、利点、および、そのアイデアは、本明細書の記載により、当業者には明らかであり、本明細書の記載から、当業者であれば容易に本発明を再現できる。以下に記載された発明の実施の形態及び具体的な実施例などは、本発明の好ましい実施態様を示すものであり、例示又は説明のために示されているのであって、本発明をこれらに限定するものではない。本明細書で開示されている本発明の意図並びに範囲内で、本明細書の記載に基づき、様々な改変並びに修飾ができることは、当業者にとって明らかである。 It should be noted that the objects, features, advantages, and ideas of the present invention are apparent to those skilled in the art by the description of the present specification, and those skilled in the art can easily reproduce the present invention from the description of the present specification. can. The embodiments and specific examples of the invention described below show preferred embodiments of the present invention and are shown for illustration or explanation purposes. It is not limited. It will be apparent to those skilled in the art that various modifications and modifications can be made based on the description herein within the intent and scope of the invention disclosed herein.
＝＝ＮＯ産生抑制剤＝＝
本発明の一実施形態は、下記構造式（Ｉ）を有する化合物ＩＫＤ-８３４４またはその薬学的に許容できる塩を有効成分として含有する、ＮＯ産生抑制剤である。このＮＯ産生抑制剤は、医薬・試薬などの薬剤、化粧品、機能性食品などに有用である。医薬としては、炎症性疾患、虚血性疾患、自己免疫性疾患、アレルギー性疾患、などに対する抗炎症剤、抗アレルギー剤などとして、利用できる。
== NO production inhibitor ==
One embodiment of the present invention is a NO production inhibitor containing the compound IKD-8344 having the following structural formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient. This NO production inhibitor is useful for drugs such as pharmaceuticals and reagents, cosmetics, and functional foods. As a pharmaceutical, it can be used as an anti-inflammatory agent, an anti-allergic agent, etc. for inflammatory diseases, ischemic diseases, autoimmune diseases, allergic diseases, and the like.
＝＝転移及び／又は浸潤抑制剤＝＝
また、本発明の他の一実施形態は、下記構造式（Ｉ）を有する化合物ＩＫＤ-８３４４またはその薬学的に許容できる塩を有効成分として含有する、固形腫瘍に対する転移及び／又は浸潤抑制剤である。ここで、治療対象の固形腫瘍は特に限定されず、血液細胞やリンパ球以外の腫瘍であればよく、例えば、線維腫、脂肪腫、粘液腫、軟骨腫、骨腫、血管腫、黒色腫、筋腫、神経腫、神経膠腫、骨肉腫、筋肉腫、線維肉腫、乳頭腫、腺腫、脳腫瘍、頚癌、食道癌、舌癌、肺癌、乳癌、膵癌、胃癌、十二指腸・空腸・回腸等の小腸癌、結腸・盲腸・直腸等の大腸癌、膀胱癌、腎癌、肝癌、胆嚢癌、前立腺癌、子宮頸癌、子宮癌、卵巣癌、甲状腺癌、咽頭癌、皮膚癌などが例示できるが、好ましくは卵巣癌である。
== Metastasis and / or Infiltration Inhibitor ==
Another embodiment of the present invention is a metastasis and / or infiltration inhibitor for a solid tumor containing the compound IKD-8344 having the following structural formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient. be. Here, the solid tumor to be treated is not particularly limited, and may be a tumor other than blood cells or lymphocytes, for example, fibromas, lipomas, mucinomas, chondromas, osteomas, hemangiomas, melanomas, etc. Small intestines such as myoma, neuroma, glioma, osteosarcoma, myoma, fibrosarcoma, papilloma, adenoma, brain tumor, cervical cancer, esophageal cancer, tongue cancer, lung cancer, breast cancer, pancreatic cancer, gastric cancer, duodenum, empty bowel, ileum, etc. Examples include cancer, colon cancer such as colon / cecum / rectum, bladder cancer, renal cancer, liver cancer, bile sac cancer, prostate cancer, cervical cancer, uterine cancer, ovarian cancer, thyroid cancer, pharyngeal cancer, and skin cancer. It is preferably ovarian cancer.
なお、薬理学的に許容される塩とは、その化合物と塩を形成するものであれば限定されないが、具体的には例えば塩酸塩、硫酸塩、硝酸塩、臭化水素酸塩、ヨウ化水素酸塩、過塩素酸塩、リン酸塩などの無機酸の付加塩、シュウ酸塩、マレイン酸塩、フマル酸塩、コハク酸塩などの有機酸の付加塩、メタンスルホン酸塩、エタンスルホン酸塩、ベンゼンスルホン酸塩、p-トルエンスルホン酸塩、カンファースルホン酸塩などのスルホン酸の付加塩、アミノ酸の付加塩などを挙げることができる。さらに、それらの化合物またはその薬理学的に許容される塩は、無水物のみならず水和物や結晶多形も含まれることは言うまでもない。 The pharmacologically acceptable salt is not limited as long as it forms a salt with the compound, but specifically, for example, hydrochloride, sulfate, nitrate, hydrobromide, hydrogen iodide. Additive salts of inorganic acids such as acid salts, perchlorates and phosphates, addition salts of organic acids such as oxalates, maleates, fumarates and succinates, methanesulphonates and ethanesulfonic acids. Examples thereof include salts, sulfonic acid addition salts such as benzene sulfonates, p-toluene sulfonates and camphor sulfonates, and amino acid addition salts. Furthermore, it goes without saying that these compounds or their pharmacologically acceptable salts include not only anhydrous but also hydrates and polymorphs of crystals.
この抗腫瘍剤は、固形腫瘍細胞の増殖を抑制したり、生存率を低下させたりするのではなく、固形腫瘍細胞の転移及び／又は浸潤を抑制することで、その効力を発揮する。従って、この抗腫瘍剤を、上記のような固形腫瘍に対する増殖抑制効果を有する抗腫瘍剤（細胞増殖抑制剤）と併用することによって、相乗効果が得られる。併用する抗腫瘍剤は、固形腫瘍に対する増殖抑制効果を有するものであれば特に限定されず、例えばシクロホスファミド、イホスファミド、メルファラン、ブスルファン、チオテパなどのナイトロジェンマスタード類や、ニムスチン、ラニムスチン、ダカルバシン、プロカルバシン、テモゾロマイド、カルムスチン、ストレプトゾトシン、ベンダムスチンなどのニトロソウレア類などのアルキル化薬；シスプラチン、カルボプラチン、オキサリプラチン、ネダプラチンなどの白金製剤；フルオロウラシルなどのピリミジン代謝阻害薬や、６−メルカプトプリンなどのプリン代謝阻害薬や、プリンアナログ、ピリミジンアナログなどのヌクレオチドアナログなどの代謝拮抗薬；アントラサイクリン系、エピポドフィロトキシン系、キノロン系などのトポイソメラーゼ阻害薬などが挙げられる。 This antitumor agent exerts its effect by suppressing metastasis and / or infiltration of solid tumor cells, rather than suppressing the growth of solid tumor cells or reducing the survival rate. Therefore, a synergistic effect can be obtained by using this antitumor agent in combination with the antitumor agent (cell proliferation inhibitor) having a proliferation inhibitory effect on solid tumors as described above. The antitumor agent to be used in combination is not particularly limited as long as it has a growth inhibitory effect on solid tumors. Alkylating agents such as nitrosoureas such as dacarbacline, procarbacline, temozolomide, carmustin, streptozotocin, bendamustine; platinum preparations such as cisplatin, carboplatin, oxaliplatin, nedaplatin; pyrimidine antimetabolites such as fluorouracil, and 6-mercaptopurine. Examples include antimetabolites such as purine metabolism inhibitors and nucleotide analogs such as purine analogs and pyrimidine analogs; topoisomerase inhibitors such as anthracyclines, epipodophylrotoxines, and quinolones.
これらの医薬の形状、投与形態、投与量は特に限定されず、患者の症状、体重、年齢、性別等に従って、最適な形状、投与形態、投与量を容易に決定できる。 The shape, administration form, and dose of these drugs are not particularly limited, and the optimum shape, administration form, and dose can be easily determined according to the patient's symptoms, body weight, age, gender, and the like.
（実施例１）ＩＫＤ-８３４４は腫瘍細胞に対し、ＮＯ産生抑制効果を有する。 (Example 1) IKD-8344 has a NO production inhibitory effect on tumor cells.
本実施例では、マウス単球由来の白血病細胞株であるＲＡＷ２６４．７を用い、ＩＫＤ-８３４４がＮＯ産生抑制効果を有することを示す。 In this example, RAW264.7, which is a leukemia cell line derived from mouse monocytes, is used to show that IKD-8344 has a NO production inhibitory effect.
（生存率の測定）１０％ＦＢＳ含有ＲＰＭＩ培地で培養したＲＡＷ２６４．７細胞の懸濁液（１ｘ１０４個／ｍＬ）を１００μＬ／ウエルで９６穴プレートに播種し、３７°Ｃ、５％ＣＯ２存在下で、２４時間培養した。そしてＩＫＤ-８３４４（終濃度０．００１、０．０１、０．１、１、１０μｇ／ｍＬ）を添加し、さらに２４時間培養した。その後、各ウエルに１０μＬのＭＴＴ溶液（Cayman社 Cat No 10009591）を添加し、２時間培養後、培地を吸引除去し、１００μＬ／ウエルでＤＭＳＯを添加した。こうしてformazanを細胞から溶出させ、５７０ｎｍの吸光度をマイクロプレートリーダー(Bio-Rad社)で測定した。各条件ごとに３連で実験を行い、その平均値を求めてグラフにプロットした（図１の折れ線グラフ）。なお、コントロールとして、ＩＫＤ-８３４４非存在下（図ではＣｏｎｔ）以外は同様の条件で実験した細胞を用いた。 (Measurement of viability) A suspension of RAW264.7 cells cultured in RPMI medium containing 10% FBS (1x10 4 cells / mL) was seeded on a 96-well plate at 100 μL / well, and 37 ° C., 5% CO 2 In the presence, it was cultured for 24 hours. Then, IKD-8344 (final concentration 0.001, 0.01, 0.1, 1, 10 μg / mL) was added, and the cells were further cultured for 24 hours. Then, 10 μL of MTT solution (Cayman Cat No 10009591) was added to each well, and after culturing for 2 hours, the medium was removed by suction, and DMSO was added at 100 μL / well. In this way, formazan was eluted from the cells, and the absorbance at 570 nm was measured with a microplate reader (Bio-Rad). Experiments were carried out in triplicate for each condition, and the average value was calculated and plotted on a graph (line graph in FIG. 1). As a control, cells tested under the same conditions except in the absence of IKD-8344 (Cont in the figure) were used.
その結果、細胞生存率は、ＩＫＤ-８３４４が０．１μｇ／ｍＬまでは有意な低下は観察されず、１μｇ／ｍＬ以上で若干の低下傾向にあった。 As a result, the cell viability was not significantly decreased up to 0.1 μg / mL for IKD-8344, and tended to decrease slightly at 1 μg / mL or more.
（ＮＯ産生量の測定）次に、１０％ＦＢＳ含有ＲＰＭＩ培地で培養したＲＡＷ２６４．７細胞の懸濁液（３ｘ１０６個／ｍＬ）を１００μＬ／ウエルで９６穴プレートに播種し、ＬＰＳ（終濃度１０ｎｇ／ｍＬ）及びＩＫＤ-８３４４（終濃度０．００１、０．０１、０．１、１、１０μｇ／ｍＬ）を添加し、３７°Ｃ、５％ＣＯ２存在下で、２４時間培養した。その後、５０μＬの上清を回収して５０μＬのGriess液（０．１％Ｎ-１-ナフチルエチレンジアミン 二塩酸，ｌ％スルファニルアミド，２．５％Ｈ３ＰＯ４）を加え、亜硝酸塩量を熱量測定法で測定した。各条件ごとに３連で実験を行い、その平均値を求めてグラフを作成した（図１の棒グラフ）。なお、コントロールとして、ＩＫＤ-８３４４非存在下でＬＰＳで刺激しない細胞（図ではＣｏｎｔ）、及びＩＫＤ-８３４４非存在下でＬＰＳで刺激した細胞（図ではＬＰＳ）を用いた。 (Measurement of NO production) Next, a suspension of RAW264.7 cells cultured in RPMI medium containing 10% FBS (3x10 6 cells / mL) was seeded on a 96-well plate at 100 μL / well, and LPS (final concentration) was used. 10 ng / mL) and IKD-8344 (final concentrations 0.001, 0.01, 0.1, 1, 10 μg / mL) were added and cultured for 24 hours at 37 ° C. in the presence of 5% CO 2. Then, 50 μL of the supernatant is collected, 50 μL of Griess solution (0.1% N-1-naphthylethylenediamine dihydrochloric acid, l% sulfanilamide, 2.5% H 3 PO 4 ) is added, and the amount of nitrite is calorific. It was measured by the measuring method. Experiments were conducted in triplicate for each condition, and the average value was calculated to create a graph (bar graph in FIG. 1). As controls, cells not stimulated with LPS in the absence of IKD-8344 (Cont in the figure) and cells stimulated with LPS in the absence of IKD-8344 (LPS in the figure) were used.
その結果、ＩＫＤ-８３４４が増加するにつれて、細胞の生存率とともにＮＯ産生量が低下するが、ＮＯ産生量低下率は細胞生存率の低下率より顕著に大きい。例えば、細胞生存率がほぼ低下しない０．１μｇ／ｍＬのＩＫＤ-８３４４の場合、ＮＯ産生量は約３分の１に低下する。また、１０μｇ／ｍＬのＩＫＤ-８３４４の場合、コントロールに比べ、生存率は半分程度に低下するが、ＮＯ産生量は１０分の１以下にまで低下する。従って、この濃度では、ＩＫＤ-８３４４は、ＮＯ産生量を細胞あたり５分の１程度に抑制する効果を有する。 As a result, as IKD-8344 increases, the NO production amount decreases with the cell viability, but the NO production decrease rate is significantly larger than the cell viability decrease rate. For example, in the case of 0.1 μg / mL IKD-8344, which does not significantly reduce cell viability, NO production is reduced to about one-third. Further, in the case of IKD-8344 of 10 μg / mL, the survival rate is reduced to about half as compared with the control, but the NO production amount is reduced to 1/10 or less. Therefore, at this concentration, IKD-8344 has the effect of suppressing the amount of NO production to about one-fifth per cell.
このように、ＩＫＤ-８３４４は、ＬＰＳで刺激した腫瘍細胞に対し、ＮＯ産生量を抑制する効果を有する。炎症巣においては、好中球やマクロファージはＮＯと同時に活性酸素の一種であるＯ２ −を産生する。ＮＯは速やかにＯ２ −と反応し、ＮＯより反応性の高いＯＮＯＯ−を生成し、この結果、炎症、アレルギー、糖尿病、動脈硬化などが引き起こされる。従って、ＩＫＤ-８３４４は、抗炎症剤、抗アレルギー剤などとして有用である。 As described above, IKD-8344 has an effect of suppressing the amount of NO production on tumor cells stimulated with LPS. In inflammatory foci, neutrophils and macrophages O 2 is one type of NO at the same time as the active oxygen - to produce. NO reacts rapidly with O 2 − to produce ONOO −, which is more reactive than NO, resulting in inflammation, allergies, diabetes, arteriosclerosis and the like. Therefore, IKD-8344 is useful as an anti-inflammatory agent, an antiallergic agent and the like.
（実施例２）ＩＫＤ-８３４４は固形腫瘍細胞に対し、細胞増殖抑制効果を有しない (Example 2) IKD-8344 does not have a cell proliferation inhibitory effect on solid tumor cells.
本実施例では、ヒト卵巣癌細胞株ＥＳ-２を用い、ＩＫＤ-８３４４が固形腫瘍細胞に対して細胞生存率抑制効果を有しないことを示す。 In this example, human ovarian cancer cell line ES-2 is used to show that IKD-8344 does not have a cell viability inhibitory effect on solid tumor cells.
１０％ＦＢＳ含有ＤＭＥＭ培地を用い、各濃度のＩＫＤ-８３４４存在下で培養したＥＳ-２に対し、実施例１と同様にして細胞生存率を測定した。ＩＫＤ-８３４４非存在下での細胞生存率を１００％としてグラフ化したものを図２に示した。 Using DMEM medium containing 10% FBS, the cell viability was measured in the same manner as in Example 1 for ES-2 cultured in the presence of IKD-8344 at each concentration. A graph showing the cell viability in the absence of IKD-8344 as 100% is shown in FIG.
ＩＫＤ-８３４４については、ヒト卵巣癌細胞株ＥＳ-２に対し、高濃度の３μg／mLでも８０％の生存率を維持し、有意な細胞増殖抑制効果は観察されなかった。これに対し、マウス白血病細胞に対しては、０．００１μg／mLの濃度で、５８．０％の増殖抑制率を示している（特開平０２-９３８２号公開公報参照）。 Regarding IKD-8344, the survival rate was maintained at 80% against the human ovarian cancer cell line ES-2 even at a high concentration of 3 μg / mL, and no significant cell proliferation inhibitory effect was observed. On the other hand, for mouse leukemia cells, the growth inhibition rate is 58.0% at a concentration of 0.001 μg / mL (see Japanese Patent Application Laid-Open No. 02-9382).
このように、固形腫瘍に対しては、ＩＫＤ-８３４４は顕著な増殖抑制効果を有しない。 As described above, IKD-8344 does not have a remarkable growth inhibitory effect on solid tumors.
（実施例３）ＩＫＤ-８３４４は固形腫瘍細胞に対して浸潤抑制効果を有する。 (Example 3) IKD-8344 has an infiltration inhibitory effect on solid tumor cells.
本実施例では、ヒト卵巣癌細胞株ＥＳ-２を用い、ＩＫＤ-８３４４が固形腫瘍細胞に対して浸潤抑制効果を有することを示す。 In this example, human ovarian cancer cell line ES-2 is used to show that IKD-8344 has an infiltration inhibitory effect on solid tumor cells.
各濃度のＩＫＤ-８３４４存在下で培養したＥＳ-２に対し、invasion assayによって浸潤を調べた。具体的には、BD Matrigel Basement Membrane Matrix membrane (Corning Inc., Corning, NY)を用いたボイデンチャンバー法を適用した。まず、ＥＳ-２細胞を各濃度のＩＫＤ-８３４４を含有し、５００μＬのＦＢＳを含有しないＤＭＥＭに懸濁し、上層に入れた。下層には上層と同じ濃度のＩＫＤ-８３４４を含有した７５０μＬの１０％ＦＢＳ含有ＤＭＥＭを満たした。３７°Ｃ、５％ＣＯ２存在下で、２４時間培養後、membraneを固定して、下の層に浸潤した細胞を残し、浸潤せずに上の層に残った細胞を綿でこすって除いた。そして、Diff-Quick solution (Sysmex, Kobe, Japan)を用いて染色し、浸潤細胞数を計測した。ＩＫＤ-８３４４非存在下での浸潤を１００％としてグラフ化したものを図３に示した。 Infiltration was examined by invasion assay for ES-2 cultured in the presence of each concentration of IKD-8344. Specifically, the Boyden chamber method using the BD Matrigel Basement Membrane Matrix membrane (Corning Inc., Corning, NY) was applied. First, ES-2 cells were suspended in DMEM containing each concentration of IKD-8344 and not containing 500 μL of FBS, and placed in the upper layer. The lower layer was filled with 750 μL of 10% FBS-containing DMEM containing IKD-8344 at the same concentration as the upper layer. After culturing for 24 hours at 37 ° C. in the presence of 5% CO 2 , the membrane was fixed to leave the cells infiltrated in the lower layer, and the cells remaining in the upper layer without infiltration were removed by rubbing with cotton. rice field. Then, staining was performed using Diff-Quick solution (Sysmex, Kobe, Japan), and the number of infiltrating cells was counted. A graph showing the infiltration in the absence of IKD-8344 as 100% is shown in FIG.
ＩＫＤ-８３４４は、ヒト卵巣癌細胞株ＥＳ-２に対して、増殖抑制効果を示さない１μg／mLまたは３μg／mLで有意な浸潤抑制効果を発揮している。 IKD-8344 exerts a significant infiltration-suppressing effect on the human ovarian cancer cell line ES-2 at 1 μg / mL or 3 μg / mL, which does not show a growth-suppressing effect.
このように、固形腫瘍に対しては、ＩＫＤ-８３４４は浸潤抑制剤として有用である。 Thus, for solid tumors, IKD-8344 is useful as an infiltration inhibitor.
（実施例４）ＩＫＤ-８３４４は固形腫瘍細胞に対して腫瘍転移抑制効果を有する。 (Example 4) IKD-8344 has a tumor metastasis inhibitory effect on solid tumor cells.
本実施例では、ヒト卵巣癌細胞株ＥＳ-２を用い、ＩＫＤ-８３４４が固形腫瘍細胞に対して細胞移動抑制効果を有することを示す。 In this example, human ovarian cancer cell line ES-2 is used to show that IKD-8344 has a cell migration inhibitory effect on solid tumor cells.
具体的には、wound healing assayによって細胞移動（migration）を調べた。まず、１０％ＦＢＳ含有ＤＭＥＭを用いて、ＥＳ-２細胞を２４穴プレートにコンフルエントになるまで培養し、ピペットマンのチップで長方形状（約１ｍｍｘ１５ｍｍ）に細胞を除去し、各濃度のＩＫＤ-８３４４を添加して２４時間培養後に写真撮影を行い、培養後の長方形の短径幅を測定した。ＩＫＤ-８３４４非存在下での長方形の幅を１００％としてグラフ化したものを図４に示した。 Specifically, cell migration was examined by a wound healing assay. First, ES-2 cells were cultured in a 24-well plate using DMEM containing 10% FBS until they became confluent, and the cells were removed in a rectangular shape (about 1 mm x 15 mm) with a Pipetman tip to obtain IKD-8344 at each concentration. After culturing for 24 hours after the addition, a photograph was taken, and the minor axis width of the rectangle after culturing was measured. FIG. 4 is a graph showing the width of the rectangle in the absence of IKD-8344 as 100%.
ＩＫＤ-８３４４は、ヒト卵巣癌細胞株ＥＳ-２に対して、増殖抑制効果を示さない０．３μｇ／ｍＬ〜３μｇ／ｍＬの濃度で有意な腫瘍細胞移動抑制効果を発揮している。 IKD-8344 exerts a significant tumor cell migration inhibitory effect on the human ovarian cancer cell line ES-2 at a concentration of 0.3 μg / mL to 3 μg / mL, which does not exhibit a growth inhibitory effect.
このように、固形腫瘍に対しては、ＩＫＤ-８３４４は腫瘍転移抑制剤として有用である。
Thus, for solid tumors, IKD-8344 is useful as a tumor metastasis inhibitor.
Claims (8)
下記構造式（Ｉ）を有する化合物またはその薬学的に許容できる塩を有効成分として含有する腫瘍転移抑制剤。
A tumor metastasis inhibitor containing a compound having the following structural formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient.
下記構造式（Ｉ）を有する化合物またはその薬学的に許容できる塩を有効成分として含有する腫瘍浸潤抑制剤。
A tumor infiltration inhibitor containing a compound having the following structural formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2017193428A JP6915865B2 (en) | 2017-10-03 | 2017-10-03 | NO production inhibitor and metastasis / infiltration inhibitor for solid tumors |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2017193428A JP6915865B2 (en) | 2017-10-03 | 2017-10-03 | NO production inhibitor and metastasis / infiltration inhibitor for solid tumors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019064973A JP2019064973A (en) | 2019-04-25 |
| JP6915865B2 true JP6915865B2 (en) | 2021-08-04 |
Family
ID=66338999
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017193428A Active JP6915865B2 (en) | 2017-10-03 | 2017-10-03 | NO production inhibitor and metastasis / infiltration inhibitor for solid tumors |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP6915865B2 (en) |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH029382A (en) * | 1988-06-28 | 1990-01-12 | Ikeda Mohandou:Kk | Novel antibiotic ikd-8344 substance and production thereof and antitumor agent with the same substance as active ingredient |
| JPH0491024A (en) * | 1990-08-03 | 1992-03-24 | Ikeda Mohandou:Kk | Anthelminthic, insecticide and antiprotozoal |
| JPH08143570A (en) * | 1994-11-16 | 1996-06-04 | Yamanouchi Pharmaceut Co Ltd | Intracellular transfer inhibitor |
| JP2005023048A (en) * | 2003-07-01 | 2005-01-27 | Institute Of Physical & Chemical Research | 3-acyl-4-alkyl-5-hydroxymethyltetronic acid derivative and medicine containing the derivative as active component |
| WO2009064444A2 (en) * | 2007-11-12 | 2009-05-22 | Bipar Sciences, Inc. | Treatment of uterine cancer and ovarian cancer with a parp inhibitor alone or in combination with anti-tumor agents |
| JP2010222307A (en) * | 2009-03-24 | 2010-10-07 | Kyushu Univ | Coral-derived therapeutic agent for inflammation and allergic disease |
| JP6452954B2 (en) * | 2013-05-16 | 2019-01-16 | 国立大学法人千葉大学 | Cancer metastasis inhibitor |
-
2017
- 2017-10-03 JP JP2017193428A patent/JP6915865B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2019064973A (en) | 2019-04-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Gou et al. | α− N− heterocyclic thiosemicarbazone Fe (III) complex: Characterization of its antitumor activity and identification of anticancer mechanism | |
| Özkay et al. | Synthesis of 2-substituted-N-[4-(1-methyl-4, 5-diphenyl-1H-imidazole-2-yl) phenyl] acetamide derivatives and evaluation of their anticancer activity | |
| Sánchez-Guadarrama et al. | Cytotoxic activity, X-ray crystal structures and spectroscopic characterization of cobalt (II), copper (II) and zinc (II) coordination compounds with 2-substituted benzimidazoles | |
| Wang et al. | Multi-targeted organometallic ruthenium (II)–arene anticancer complexes bearing inhibitors of poly (ADP-ribose) polymerase-1: A strategy to improve cytotoxicity | |
| AU2013235425A1 (en) | Inhibition of MCL-1 and/or BFL-1/A1 | |
| Krasnovskaya et al. | Novel copper-containing cytotoxic agents based on 2-thioxoimidazolones | |
| CN105358549B (en) | Quinazoline derivant | |
| US12103939B2 (en) | Solid pharmaceutical gold-based composition | |
| Mahdy et al. | Synthesis, characterization, and biological activity of Co (II) and Zn (II) complexes of imidazoles-based azo-functionalized Schiff bases | |
| Li et al. | Synthesis and biological evaluation of novel alkylated polyamine analogues as potential anticancer agents | |
| CN110944628A (en) | Treatment of cancer with EZH2 inhibitors | |
| Tuluce et al. | Antiproliferative and apoptotic role of novel synthesized Cu (II) complex with 3-(3-(4-fluorophenyl) Triaz-1-en-1-yl) benzenesulfonamide in common cancer models | |
| JP6915865B2 (en) | NO production inhibitor and metastasis / infiltration inhibitor for solid tumors | |
| Zhang et al. | Series of Desloratadine Platinum (IV) Hybrids Displaying Potent Antimetastatic Competence by Inhibiting Epithelial–Mesenchymal Transition and Arousing Immune Response | |
| CA2890108C (en) | Method for treating prostate cancer | |
| ES2978159T3 (en) | Heat shock factor (HSF) inhibitors and their uses | |
| US11571430B2 (en) | Platinum(II) ammine selenourea complexes and methods of treating cancer | |
| EP3814354B1 (en) | Purine compounds and method for the treatment of cancer | |
| AU2017100874A4 (en) | Method for inhibiting the expression of ABC transporter protein | |
| Peng et al. | Novel N-phenyl-2-(aniline) benzamide hydrochloride salt development for colon cancer therapy | |
| Al-Nasser et al. | A Novel N-heterocyclic Carbene Compound Exhibits Anticancer Properties by Inducing Apoptosis, Inhibiting Cell Migration, and Improving Standard Therapeutic Efficacy in Human Colorectal Cancer Cell Lines | |
| AU2016101491A4 (en) | Cobalt-polypyridyl complex for treatment of cancer, a pharmaceutical composition and a kit comprising it | |
| Gözelle et al. | Synthesis of 2-Substitutedbenzimidazolium Tetrachloroplatinate (II) Compounds and Their Cytotoxic Activities on Different Cell Lines | |
| US20170258793A1 (en) | Method for treating prostate cancer | |
| Stacy | Thiosemicarbazones Target Multiple Resistance Pathways in Cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20200928 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20210611 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20210622 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20210708 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6915865 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |